Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Capital Expenditures (2022 - 2025)

Envoy Medical's Capital Expenditures history spans 4 years, with the latest figure at $49000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 94.96% year-over-year to $49000.0; the TTM value through Sep 2025 reached -$478000.0, down 131.14%, while the annual FY2024 figure was $980000.0, 540.52% up from the prior year.
  • Capital Expenditures for Q3 2025 was $49000.0 at Envoy Medical, up from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $972000.0 in Q3 2024 and bottomed at -$534000.0 in Q4 2024.
  • The 4-year median for Capital Expenditures is $45000.0 (2022), against an average of $102500.0.
  • The largest YoY upside for Capital Expenditures was 3836.36% in 2024 against a maximum downside of 2642.86% in 2024.
  • A 4-year view of Capital Expenditures shows it stood at $41000.0 in 2022, then crashed by 48.78% to $21000.0 in 2023, then plummeted by 2642.86% to -$534000.0 in 2024, then skyrocketed by 109.18% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Capital Expenditures are $49000.0 (Q3 2025), $1000.0 (Q2 2025), and $6000.0 (Q1 2025).